Syngene International Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Syngene International Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Last Updated on: Oct 25, 2026
Key Highlights
The Latest Trading Price of Syngene International Ltd is ₹ 366.9 as of 23 Oct 15:30
. The P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN%
The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57%
The Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .
About Syngene International Ltd
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.
Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.
About Yatharth Hospital & Trauma Care Services Ltd
Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC.
Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care.
The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care
hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.
FAQs for the comparison of Syngene International Ltd and Yatharth Hospital & Trauma Care Services Ltd
Which company has a larger market capitalization, Syngene International Ltd or Yatharth Hospital & Trauma Care Services Ltd?
Market cap of Syngene International Ltd is 14,810 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,978 Cr
What are the key factors driving the stock performance of Syngene International Ltd and Yatharth Hospital & Trauma Care Services Ltd?
The stock performance of Syngene International Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Syngene International Ltd and Yatharth Hospital & Trauma Care Services Ltd?
As of October 25, 2026, the Syngene International Ltd stock price is INR ₹366.9. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹931.85.
How do dividend payouts of Syngene International Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?
To compare the dividend payouts of Syngene International Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.